Modality
Peptide
MOA
CDK4/6i
Target
GLP-1R
Pathway
Amyloid
Alzheimer'sFSGS
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
~Jan 2022
→ ~Apr 2023
Phase 3
~Jul 2023
→ ~Oct 2024
NDA/BLA
Jan 2025
→ Oct 2026
NDA/BLACurrent
NCT04421497
2,944 pts·FSGS
2025-01→2026-10·Active
2,944 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-10-197mo awayPh3 Readout· FSGS
Trial Timeline
2025Q2Q3Q42026Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph3 Readout
2026-10-19 · 7mo away
FSGS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04421497 | NDA/BLA | FSGS | Active | 2944 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| RHH-1969 | Roche | Approved | BET | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 |